Maximizing efficacy and reducing the emergence of resistance

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 1, 2003, Pages 37-42

  Wise, Richard ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Fluoroquinolones; Pharmacodynamics; Resistance

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; HUMAN; LEGIONELLA PNEUMOPHILA; LISTERIA MONOCYTOGENES; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 0038101634     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg210     Document Type: Review

References (44)

1. Schentag, J. J. (1989). Clinical significance of antibiotic tissue penetration. Clinical Pharmacokinetics 16, Suppl. 1, 25-31.
2. Nix, D. E., Goodwin, S. D., Peloquin, C. A., Rotella, D. L. & Schentag, J. J. (1991). Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrobial Agents and Chemotherapy 35, 1953-9.
3. Estes, L. (1998). Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clinic Proceedings 73, 1114-22.
4. Drusano, G. L. & Craig, W. A. (1997). Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9, Suppl. 3, 38-44.
5. Wiedemann, B. (1999). In vitro pharmacodynamics of moxifloxacin against respiratory pathogens. In Moxifloxacin in Practice (Adam, D. & Finch, R. G., Eds), pp. 17-25. Maxim Medical, Oxford, UK.
6. Dalhoff, A. (1996). Antibacterial efficacy of fluctuating concentrations of BAY 12-8039 simulating human serum kinetics. In Program and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F026. American Society for Microbiology, Washington, DC, USA.
7. Dalhoff, A. (1997). Pharmacodynamics of quinolones. In Program and Abstracts of the Twentieth International Congress of Chemotherapy, Sydney, Australia, 1997 Abstract 2204. International Society of Chemotherapy, London, UK.
8. MacGowan, A. P. (1999). Pharmacodynamics of moxifloxacin. In Moxifloxacin in Practice (Adam, D. & Finch, R. G., Eds), pp. 5-15. Maxim Medical, Oxford, UK.
9. Hyatt, J. M., McKinnon, P. S., Zimmer, G. S. & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics 28, 143-60.
10. MacGowan, A. P. (1999). In vitro models of infection: pharmacokinetic/pharmacodynamic correlates. In First International Moxifloxacin Symposium (Mandell, L., Ed.), pp. 104-10. Springer-Verlag, Berlin, Germany.
11. Zinner, S. H. (1999). In vitro models as predictors of the antimicrobial effect of moxifloxacin and other fluoroquinolones. In First International Moxifloxacin Symposium (Mandell, L., Ed.), pp. 98-103. Springer-Verlag, Berlin, Germany.
12. White, C. A., Toothaker, R. D., Smith, A. L. & Slattery, J. T. (1989). In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli. Antimicrobial Agents and Chemotherapy 33, 1046-51.
13. Caillon, J., Juvin, M. E., Pirault, J. L. & Drugeon, H. B. (1989). Bactericidal effect of daptomycin (LY 146032) compared with vancomycin and teicoplanin against Gram-positive bacteria. Pathologie-biologie 37, 540-8.
14. Stahlmann, R. & Lode, H. (1998). Concentration-effect relationship of the fluoroquinolones. In Quinolone Antibacterials (Kuhlmann, J., Dalhoff, A. & Zeiler, H.-J., Eds), pp. 407-20. Springer, Heidelberg, Germany.
15. Deziel-Evans, L. M., Murphy, J. E. & Job, M. L. (1986). Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clinical Pharmacy 5, 319-24.
16. Moore, R. D., Lietman, P. S. & Smith, C. R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155, 93-9.
17. Schentag, J. J. (1990). Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scandinavian Journal of Infectious Diseases 74, Suppl., 218-34.
18. Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-60.
19. Schentag, J. J., Nix, D. E., Forrest, A. & Adelman, M. H. (1996). AUIC - the universal parameter within the constraint of a reasonable dosing interval. Annals of Pharmacotherapy 30, 1029-31.
20. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
21. Schentag, J. J. (1994). The relationship between ciprofloxacin blood concentrations, MIC values, bacterial eradication and clinical outcome in patients with nosocomial pneumonia. In Ciprofloxacin iv. Defining its Role in Serious Infection (Garrad, C., Ed.), pp. 49-57. Springer-Verlag, Berlin, Germany.
22. Craig, W. A., Ebert, S. & Moffatt, J. (1993). Pharmacodynamic activity of Bay y 3118 in animal infection models. In Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1485, p. 391. American Society for Microbiology, Washington, DC, USA.
23. Watanabe, Y., Ebert, S. & Craig, W. A. (1992). AUC/MIC ratio is unifying parameter for comparison of in vivo activity among fluoroquinolones. In Program and Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 42, p. 117. American Society for Microbiology, Washington, DC, USA.
24. Andrews, J. M., Honeybourne, D., Jevons, G. & Wise, R. (1998). Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid, and alveolar macrophages following a single 400mg oral dose. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A29, p. 9. American Society for Microbiology, Washington, DC, USA
25. Wise, R. (1991). Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. American Journal of Medicine 91, 67S-70S.
26. Scorneaux, B. & Tulkens, P. M. (1992). Activities of macrolides (ML) and fluoroquinolones (FQ) against Legionella pneumophila (L. p.) in a model of J774 macrophages (MØ) in relation to their cellular accumulation. In Program and Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 1701, p. 394. American Society for Microbiology, Washington, DC, USA.
27. Scorneaux, B. & Tulkens, P. M. (1992). Activities of azithromycin (Az), sparfloxacin (Sp), gentamicin (Gm) and ampicillin (Am) against a series of facultative and obligatory intracellular parasites in a model of J774 macrophages (MØ). In Program and Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 1706, p. 395. American Society for Microbiology, Washington, DC, USA.
28. Bergogne-Berezin, E. (2002). Clinical role of protein binding of quinolones. Clinical Pharmacokinetics 41, 741-50.
29. Grasela, D. M. (2000). Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clinical Infectious Diseases 31, Suppl. 2, S51-8.
30. Turnidge, J. (11999). Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58, Suppl. 2, 29-36.
31. Norrby, S. R. (1999). Levofloxacin. Expert Opinion on Pharmacotherapy 1, 109-19.
32. Stass, H., Dalhoff, A., Kubitza, D. & Schuhly, U. (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrobial Agents and Chemotherapy 42, 2060-5.
33. Wise, R., Gillett, A. P., Cadge, B., Durham, S. R. & Baker, S. (1980). The influence of protein binding upon tissue fluid levels of six β-lactam antibiotics. Journal of Infectious Diseases 142, 77-82.
34. Wise, R., Mortiboy, D., Child, J. & Andrews, J. M. (1996). Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy 40, 47-9.
35. Johnson, J. H., Cooper, M. A., Andrews, J. M. & Wise, R. (1992). Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrobial Agents and Chemotherapy 36, 2444-6.
36. Forrest, A., Chodosh, S., Amantea, M. A., Collins, D. A. & Schentag, J. J. (1997). Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 45-57.
37. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.
38. Wise, R. (1999). A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clinical Drug Investigation 17, 365-87.
39. Schentag, J. J. (2002). Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. Journal of Chemotherapy 14, Suppl. 2, 13-21.
40. Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H. et al. (1998). Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy 42, 521-7.
41. Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C., Kibsey, P. et al. (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
42. Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D. et al. (2002). Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrobial Agents and Chemotherapy 46, 1295-301.
43. Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A. et al. (2002). Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrobial Agents and Chemotherapy 46, 680-8.
44. Gill, M. J., Brenwald, N. P. & Wise, R. (1999). Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 187-9.